The Senior Leadership is responsible for the overall planning and operations ofthe programs and activities ofthe Robert H. Lurie Comprehensive Cancer Center. The Senior Leadership is comprised ofthe Director, Deputy Director and nine Associate Directors, and has undergone a number of changes during the current project period. Steven Rosen, MD has continued as Director since 1989, and Leonidas Platanias, MD, PhD has continued as Deputy Director since his recruitment to Northwestern in 2002. Among the Associate Directors, also continuing in their positions are (1) Jonathan Licht, MD, for Clinical Sciences Research, (2) Mr. Timothy Volpe for Administration, (3) Al B. Benson, 111, MD for Clinical Investigations, and (4) Julian Schink, MD for Clinical Affairs. Changes among the Associate Directors include (1) Thomas O'Halloran, PhD, who assumed the role of Associate Director for Basic Sciences Research in September, 2007, (2) David Cella, PhD, who assumed the role of Associate Director for Cancer Prevention and Control Research in April, 2009, (3) John Crispino, PhD, who assumed the role of Associate Director for Education and Training in August, 2008. In addition, Jill Pelling, PhD, who served as Associate Director for Translational Research since 2004, retired on August 31, 2012, and a search is currently underway for her replacement. Finally, since the time of the last review, a new Senior Leadership position of Associate Director for Equity and Minority Health has been established to further strengthen the Lurie Cancer Center's long-standing commitment to outreach and service to minority and medically under-served populations. CCSG support is requested for all Senior Leadership positions except those of Associate Director for Clinical Investigations and Associate Director for Clinical Affairs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA060553-20
Application #
8761082
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$533,400
Indirect Cost
$190,343
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Yang, Ruiguo; LemaƮtre, Vincent; Huang, Changjin et al. (2018) Monoclonal Cell Line Generation and CRISPR/Cas9 Manipulation via Single-Cell Electroporation. Small 14:e1702495
Buglak, Nicholas E; Jiang, Wulin; Bahnson, Edward S M (2018) Cinnamic aldehyde inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in Zucker Diabetic Fatty rats. Redox Biol 19:166-178
Takahashi, Satoe; Sun, Willy; Zhou, Yingjie et al. (2018) Prestin Contributes to Membrane Compartmentalization and Is Required for Normal Innervation of Outer Hair Cells. Front Cell Neurosci 12:211
Zheng, Jianbin; Chen, Long; Skinner, Owen S et al. (2018) ?-Glucocerebrosidase Modulators Promote Dimerization of ?-Glucocerebrosidase and Reveal an Allosteric Binding Site. J Am Chem Soc 140:5914-5924
Kenney, Grace E; Dassama, Laura M K; Pandelia, Maria-Eirini et al. (2018) The biosynthesis of methanobactin. Science 359:1411-1416
Joyce, Brian T; Zheng, Yinan; Zhang, Zhou et al. (2018) miRNA-Processing Gene Methylation and Cancer Risk. Cancer Epidemiol Biomarkers Prev 27:550-557
Chu, Lan H; Indramohan, Mohanalaxmi; Ratsimandresy, Rojo A et al. (2018) The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat Commun 9:996
Symes, Yael R; Barrington, Clare; Austin, Jane et al. (2018) Advice to patients undergoing stem cell transplant: Content analysis of survivor peer support narratives. J Health Psychol 23:818-828
Lewis, Phillip L; Green, Richard M; Shah, Ramille N (2018) 3D-printed gelatin scaffolds of differing pore geometry modulate hepatocyte function and gene expression. Acta Biomater 69:63-70
Ugolkov, Andrey V; Bondarenko, Gennadiy I; Dubrovskyi, Oleksii et al. (2018) 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs 29:717-724

Showing the most recent 10 out of 1972 publications